Celebrex (celecoxib) Dec 2004
Audience: Rheumatologists and other healthcare professionals
FDA notified healthcare professionals that, based on emerging information, including preliminary reports from one of several long term National Institutes of Health (NIH) prevention studies, the risk of cardiovascular events may be increased in patients receiving Celebrex. FDA is analyzing all available information from these studies to determine whether additional regulatory action is needed.
[December 17, 2004 - Drug Information Page - FDA]